QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-16

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...

 why-is-gene-therapy-developer-benitec-biopharma-stock-trading-higher-on-thursday

Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces inte...

Core News & Articles
Market-Moving News for April 18th
04/18/2024 12:35:31

BPTH: 98% | Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in...

 benitec-biopharma-reports-oversubscribed-private-placement-financing-of-40m

Benitec Biopharma announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5.749 million...

 benitec-biopharma-files-for-mixed-shelf-of-up-to-125m

-SEC Filing

 jmp-securities-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-10

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...

 benitec-biopharma-q2-eps-264-up-from-334-yoy

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(2.64) per share. This is a 20.96 percent increase over losses of...

 jmp-securities-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-8

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...

 benitec-biopharma-q1-eps-276-up-from-799-yoy

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(2.76) per share. This is a 65.46 percent increase over losses of...

 jmp-securities-maintains-market-outperform-on-benitec-biopharma-raises-price-target-to-6

JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the pri...

 why-promis-neurosciences-shares-are-trading-higher-by-33-here-are-20-stocks-moving-premarket

Gainers Axcella Health Inc. (NASDAQ: AXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION